Genmab Signs Cancer Drug Deal Worth Up to $1.1B

Danish biopharmaceutical company Genmab A/S Thursday said it has granted Janssen Biotech Inc. an exclusive global license to develop and commercialize its Daratumumab treatment for multiple myeloma, a form of cancer found in bone marrow, in a deal that could be worth up to $1.1 billion.
MarketWatch